Pacira BioSciences, Inc.
PCRX
$27.00
-$0.14-0.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.85% | 4.40% | 3.15% | 1.88% | 1.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.85% | 4.40% | 3.15% | 1.88% | 1.22% |
| Cost of Revenue | -4.20% | -7.47% | -9.80% | -16.84% | -14.17% |
| Gross Profit | 8.40% | 11.81% | 11.67% | 16.42% | 12.65% |
| SG&A Expenses | 9.15% | 4.74% | 4.96% | 3.65% | 5.86% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.68% | -0.86% | -1.96% | -3.70% | -1.38% |
| Operating Income | 11.74% | 50.90% | 48.07% | 60.48% | 23.12% |
| Income Before Tax | -202.28% | -653.94% | 2,276.77% | 597.48% | 363.85% |
| Income Tax Expenses | 84.61% | 1,122.49% | 72,554.90% | 413.11% | 857.42% |
| Earnings from Continuing Operations | -337.30% | -1,399.31% | 1,492.14% | 774.03% | 163.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -337.30% | -1,399.31% | 1,492.14% | 774.03% | 163.72% |
| EBIT | 11.74% | 50.90% | 48.07% | 60.48% | 23.12% |
| EBITDA | 8.26% | 23.13% | 19.23% | 20.92% | 7.22% |
| EPS Basic | -339.16% | -1,437.02% | 1,451.33% | 780.20% | 155.39% |
| Normalized Basic EPS | 28.47% | 109.24% | 138.03% | 258.76% | 124.65% |
| EPS Diluted | -359.04% | -8,731.60% | 696.98% | 530.67% | 255.66% |
| Normalized Diluted EPS | 34.86% | 112.47% | 126.85% | 226.21% | 106.34% |
| Average Basic Shares Outstanding | 0.05% | 0.49% | 0.97% | 1.24% | 1.54% |
| Average Diluted Shares Outstanding | -2.09% | 2.54% | 9.04% | 9.59% | 6.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |